Long‑Term Efficacy and Safety of Duvakitug in Inflammatory Bowel Disease

Teva Pharmaceuticals, in partnership with Sanofi, announced that the investigational antibody duvakitug continued to deliver clinically meaningful benefits in patients with ulcerative colitis (UC) and Crohn’s disease (CD) over a 44‑week extension period. The data, derived from a randomized, double‑blind study, reinforce the therapeutic potential of duvakitug as a long‑term maintenance option for moderate‑to‑severe disease.

Study Design and Patient Cohort

Following a 14‑week induction phase, patients who achieved clinical response were randomized to receive either 450 mg or 900 mg of duvakitug subcutaneously every four weeks. The extension study enrolled a diverse cohort of UC and CD patients across multiple regions, providing a robust dataset for evaluating sustained efficacy and safety.

Clinical Outcomes

Across both indications, duvakitug produced:

  • Sustained rates of clinical remission – patients maintained symptom control throughout the maintenance period.
  • Consistent clinical response – a durable reduction in disease activity scores was observed.
  • Endoscopic improvement – objective mucosal healing was documented in a substantial proportion of participants.
  • Dose‑response relationship – the 900 mg cohort generally demonstrated a modestly stronger effect, suggesting a potential for dose optimization in future trials.

These results are aligned with earlier short‑term studies, indicating that the antibody’s benefits are not transient but persist with continued treatment.

Safety Profile

The safety data remained consistent with earlier findings:

  • Adverse events (AEs) were predominantly mild or moderate.
  • No new safety signals emerged during the 44‑week period.
  • Common AEs included upper respiratory tract infections and nasopharyngitis.
  • Rare events such as hypertension and anemia were infrequently reported and did not raise new concerns.

The absence of unexpected safety issues supports the drug’s tolerability for long‑term use.

Biomarker Insights and Mechanistic Rationale

Biomarker analyses presented at the United European Gastroenterology Week revealed that duvakitug:

  • Reduces circulating inflammatory markers – indicative of systemic anti‑inflammatory activity.
  • Affects tissue remodeling pathways – potentially mitigating fibrosis, a key driver of disease progression.
  • Modulates the TL1A pathway – a critical mediator in inflammatory bowel disease (IBD), reinforcing the antibody’s targeted mechanism.

These mechanistic insights provide a strong biological foundation for the observed clinical outcomes.

Strategic Development and Commercialization

Teva and Sanofi maintain a co‑development and co‑commercialization framework:

  • Teva leads in European markets.
  • Sanofi oversees North America, Japan, and other regions.

The partnership plans to expand duvakitug’s clinical indications to include:

  • Hidradenitis suppurativa – a chronic inflammatory skin condition.
  • Fibrostenotic Crohn’s disease – a subset of CD characterized by stricturing lesions.

Phase‑three trials for UC and CD are ongoing, with the objective of securing regulatory approvals and defining duvakitug’s positioning within the competitive landscape of biologics and small‑molecule therapies.

Broader Economic and Industry Context

The continued success of duvakitug illustrates several broader trends:

  • Growth of antibody‑based therapies in chronic inflammatory diseases, driven by advances in target identification and biologic manufacturing.
  • Strategic alliances between mid‑sized manufacturers (Teva) and large multinational pharma (Sanofi) to share risk and capitalize on complementary market strengths.
  • Emphasis on biomarkers to predict response and tailor therapy, aligning with personalized medicine initiatives.

In a market increasingly saturated with biologic options, duvakitug’s demonstrated durability and safety may position it favorably among patients and payers seeking long‑term disease control with a manageable safety profile.

The long‑term data presented by Teva and Sanofi strengthen duvakitug’s case as a durable maintenance therapy for ulcerative colitis and Crohn’s disease, while ongoing studies aim to expand its therapeutic footprint and confirm its value proposition across diverse patient populations.